Immunovant, Inc. Common Stock

IMVT trades with a striking 21.91% short interest—nearly a quarter of float—despite a $5.9B market cap suggesting institutional conviction. The stock's RSI of 56.9 sits in neutral territory, neither oversold nor overbought, indicating room to move in either direction. The absence of a P/E ratio signals the company likely isn't yet profitable, typical for biotech plays where clinical progress or regulatory catalysts drive valuations more than earnings. This combination of elevated shorting pressure, mid-range momentum, and pre-profitability status creates a volatile setup sensitive to binary events. The positioning suggests skeptics believe execution risk outweighs pipeline potential, while longs may be betting on a clinical inflection point.